Drug

Analyst: Biogen's aducanumab is not getting approved absent a deus ex machina

6 days ago   |   By Fierce Biotech

Baird analyst Brian Skorney has dismissed the chances of Biogen winning approval for its Alzheimer's disease drug aducanumab. Skorney's skeptical reading comes days before Biogen is due to discuss data from its phase 3 program at the Clinical Trials on Alzheimer's Disease annual congress.
Read more ...

 


Search by Tags

   Drug      Drugs      Clinical  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

AstraZeneca Taps Gatehouse Bio to Identify Potential Drug Targets

AstraZeneca Taps Gatehouse Bio to Identify Potential Drug Targets

After joining AstraZeneca's Boston Bio Hub incubator last year, Gatehouse Bio is now teaming up with the pharma company to identify potential drug targets in respiratory and... Read more ...

IAmScience Mannie Liscum

IAmScience Mannie Liscum

For Mannie Liscum, thinking is a privilege, and his job gives him the chance to be fascinated by human's capacity to conceptualize and learn new things. “It's my goal to use as... Read more ...

Alert: Johnson Fistel Investigates Proposed Sale of ArQule, Inc.; Is $20 a...

SAN DIEGO, Dec. 9, 2019 /PRNewswire/ - Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of ArQule, Inc. breached... Read more ...

New Sanofi CEO Hudson adds next-gen cancer drug tech to the R&D quest...

When Paul Hudson lays out his R&D vision for Sanofi tomorrow, he will have a new slate of interleukin therapies and a synthetic biology platform to boast about. The French... Read more ...

AveXis Inc.: Senior Scientific Training Specialist - cGMP Gene Therapy

AveXis Inc.: OverviewReady to join a team committed to developing and commercializing gene therapies for patients and families devastated by rare neurological gene San Diego... Read more ...

Process Engineer I - Genentech - Oceanside, CA

Focus will be on one or more areas such as design, implementation and/or start-up of new and/or existing facilities with respect to process and/or clean utility...From... Read more ...

Pineoblastoma segregates into molecular sub-groups with distinct...

Abstract Pineoblastomas are rare, aggressive pediatric brain tumors of the pineal gland with modest overall survival despite intensive therapy. We sought to define the clinical... Read more ...

The majority of A-to-I RNA editing is not required for mammalian homeostasis

Abstract Background Adenosine-to-inosine RNA editing, mediated by ADAR1 and ADAR2, occurs at tens of thousands to millions of sites across mammalian transcriptomes. A-to-I... Read more ...

CRISPR System: A High-throughput Toolbox for Research and Treatment of...

Abstract In recent years, the innovation of gene-editing tools such as the CRISPR/Cas9 system improves the translational gap of treatments mediated by gene therapy. The... Read more ...

Exploration of cryptic organic photosensitive compound as Zincphyrin IV in...

Abstract Zincphyrin IV is a potential organic photosensitizer which is of significant interest for applications in biomedicine, materials science, agriculture , and chemistry... Read more ...